Overview

Corneal Collagen Cross-linking for Progressive Keratoconus

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
Phase:
Phase 3
Details
Lead Sponsor:
Avedro, Inc.
Glaukos Corporation
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Riboflavin